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ABSTRACT
BACKGROUND: Dementia is a highly prevalent condition worldwide. Its chronic and progressive presen-
tation has an impact on physical and psychosocial characteristics and on public healthcare. Our aim was to 
summarize evidence from Cochrane reviews on non-pharmacological treatments for cognitive disorders 
and dementia. 
DESIGN AND SETTING: Review of systematic reviews, conducted in the Discipline of Evidence-Based 
Medicine, Escola Paulista de Medicina, Universidade Federal de São Paulo.
METHODS: Cochrane reviews on non-pharmacological interventions for cognitive dysfunctions and/or 
type of dementia were included. For this, independent assessments were made by two authors. 
RESULTS: Twenty-four reviews were included. These showed that carbohydrate intake and validation 
therapy may be beneficial for cognitive disorders. For dementia, there is a potential benefit from physi-
cal activity programs, cognitive training, psychological treatments, aromatherapy, light therapy, cognitive 
rehabilitation, cognitive stimulation, hyperbaric oxygen therapy in association with donepezil, functional 
analysis, reminiscence therapy, transcutaneous electrical stimulation, structured decision-making on feed-
ing options, case management approaches, interventions by non-specialist healthcare workers and spe-
cialized care units. No benefits were found in relation to enteral tube feeding, acupuncture, Snoezelen 
stimulation, respite care, palliative care team and interventions to prevent wandering behavior. 
CONCLUSION: Many non-pharmacological interventions for patients with cognitive impairment and dementia 
have been studied and potential benefits have been shown. However, the strength of evidence derived from 
these studies was considered low overall, due to the methodological limitations of the primary studies. 
RESUMO
INTRODUÇÃO: Demência é uma condição com alta prevalência e incidência global. Sua característica 
crônica e progressiva tem impacto em aspectos físicos, psicossociais e na saúde pública. Nosso objetivo 
foi resumir evidências de revisões Cochrane sobre intervenções não farmacológicas para distúrbios cog-
nitivos e demências.
TIPO DE ESTUDO E LOCAL: Revisão de revisões sistemáticas conduzida na Disciplina de Medicina Basea-
da em Evidências da Escola Paulista de Medicina, Universidade Federal de São Paulo.
MÉTODOS: Foram incluídas revisões Cochrane sobre intervenções não farmacológicas para disfunções cog-
nitivas e/ou qualquer tipo de demência, após a avaliação realizada de forma independente por dois autores.
RESULTADOS: Vinte e quatro revisões foram incluídas. As revisões mostraram que ingestão de carboidra-
tos e a terapia de validação podem ser benéficas para distúrbios cognitivos. Para demência, existe bene-
fício potencial de programas de atividade física, treino cognitivo, tratamentos psicológicos, aromaterapia, 
terapia com luz, reabilitação cognitiva, estimulação cognitiva, oxigenoterapia hiperbárica associada a do-
nepezila, análise funcional, terapia de reminiscência, estimulação elétrica transcutânea, decisão estrutura-
da em opções de alimentação, abordagem de gestão de casos e intervenções aplicadas por trabalhadores 
na área de saúde não especialistas e por unidades de cuidado especializado. Não foram encontrados 
benefícios para alimentação por sonda entérica, acupuntura, estimulação de Snoezelen, cuidados de re-
pouso, equipe de cuidados paliativos e intervenções para prevenir comportamento de perambulação.
CONCLUSÃO: Várias intervenções não farmacológicas para pacientes com comprometimento cognitivo e 
demência têm sido estudadas, mostrando benefícios potenciais. Entretanto, a força de evidência derivada 
desses estudos é em geral considerada baixa, devido às limitações metodológicas dos estudos primários.
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INTRODUCTION
Dementia has been considered by the World Health Organization 
to be a public health priority since 2012,1 because of its high esti-
mated prevalence and incidence. A report published in 2016 esti-
mated that 47.5 million people have dementia worldwide and 
this number is expected to almost triple by 2050, to reach 135.5 
million.2 Because of the chronic and progressive nature of this 
condition, the socioeconomic impact of dementia is extremely 
important. As a consequence of the estimated increase in preva-
lence, increases in the familial and societal burden and an even 
more significant impact on healthcare costs can be expected.3,4 
Treatment and management of dementia are challenging 
because of the patients’ diminished ability to adhere to thera-
peutics and to report adverse effects.5 Also, dementia is not a 
 single condition: rather, it comprises distinct diseases with  different 
pathophysiological mechanisms. The therapeutic and preventive 
strategies depend particularly on understanding  the  etiology and 
other factors such as  clinical features, stage of dementia and family 
support. Some of the most common pharmacological agents are 
cholinesterase inhibitors,6  memantine,7 memantine combined with 
 cholinesterase  inhibitors8,9 and antioxidants.10,11 There are many 
non-pharmacological  therapies and some of them show little, if 
any, evidence of benefit regarding dementia.
A quick search on MEDLINE (via PubMed), using the 
MeSH term “dementia” and applying a filter to identify clinical 
trials, retrieved an average of 268 (153-334) published papers per 
year over the last 10 years. The high number of studies published 
over recent years and the clinical importance of this issue have 
provided the impulse for comprehensive research syntheses such 
as this review of reviews.
OBJECTIVES 
To identify and summarize Cochrane systematic reviews  focusing 
on non-pharmacological interventions to treat  cognitive impair-
ment and dementia, regardless of etiology, and to present their 
findings in accordance with the quality of the evidence.
METHODS 
Design 
Review of Cochrane systematic reviews on interventions to treat 
cognitive impairment and dementia. 
Setting
Discipline of Evidence-Based Medicine of Escola Paulista de 
Medicina, Universidade Federal de São Paulo (UNIFESP). 
Criteria for including reviews
• Types of studies 
We included the latest version of completed Cochrane systematic 
reviews, without imposing any restriction on publication date. 
Protocols relating to systematic reviews and reviews that were 
coded as “withdrawn” in the Cochrane Database of Systematic 
Reviews (CDSR) were not included. 
• Types of participants
Patients diagnosed with cognitive impairment or demen-
tia, regardless of etiology, including (but not limited to) mild 
cognitive impairment, vascular dementia, Alzheimer, mixed 
dementia and dementia secondary to other neurodegenera-
tive diseases.
• Types of intervention
Non-pharmacological interventions including (but not limited 
to) psychological, social and educational interventions, acupunc-
ture, physical exercise and physical therapy. 
• Types of outcomes 
Clinical, social and laboratory outcomes, as reported in the sys-
tematic reviews.
Search for reviews 
We conducted a systematic search in the Cochrane Database of 
Systematic Reviews (CDSR) (via Wiley) on December 19, 2016, 
using a sensitive search strategy (Table 1). 
Selection of systematic reviews 
Two reviewers independently evaluated titles and abstracts of 
records initially retrieved on the basis of the inclusion criteria. 
Disagreements were solved by reaching a consensus. 
Presentation of the results
We presented the results from the systematic reviews included 
through a narrative structure (qualitative synthesis). 
RESULTS 
Search results
The initial search retrieved 183 reviews. However, only 24 ful-
filled our inclusion criteria.12-35
Table 1. Search strategy (December 19, 2016)
#1: “Dementia” in Title, Abstract, Keywords
#2: “Alzheimer Disease” in Title, Abstract, Keywords
#3: Alzheimer in Title, Abstract, Keywords
#4: “Cognitive Dysfunction” in Title, Abstract, Keywords
#5: #1 OR #2 OR #3 OR #4
#6: #5 in Cochrane Reviews
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Results from systematic reviews
Among the 24 systematic reviews included, two (~8%) focused 
on vascular dementia, two (~8%) focused on dementia second-
ary to other diseases and 16 (~66.6%) focused on all types of 
dementia. Additionally, one study (~4%) focused on cognition as 
a broader topic, two (~8%) focused on both dementia and mild 
cognitive impairment and one (~4%) on mental disorders as a 
broader topic. Three reviews (12.5%) assessed caregivers’ out-
comes, and six (25%) focused on interventions relating to health-
care systems.
A brief summary of the systematic reviews included is pre-
sented below. The issues addressed, the main findings from each 
intervention and the quality of the evidence (based on the GRADE 
approach) are presented in Tables 2, 3 and 4.12-36
Table 2. Characteristics, main findings and quality of evidence from systematic reviews focusing on patient-directed interventions
Intervention Population/comparison Benefits, harms and safety
Evidence quality 
(GRADE approach*)
Physical exercise 
programs13
Dementia/usual care; 
social group activity.
Benefit: activities of daily living.
No effect: cognition; neuropsychiatric symptoms; depression.
Very low to 
moderate
Cognitive training15
Multiple sclerosis/any 
type of care.
Benefit: memory span; working memory.
No effect: emotional functions; attention; information processing speed; 
immediate verbal memory; executive functions; depression.
Very low to low
Cognitive training 
plus other 
neuropsychological 
rehabilitation methods15
Multiple sclerosis/any 
type of care.
Benefit: attention; immediate verbal memory; delayed memory.
No effect: emotional functions; attention; information processing speed; 
everyday cognitive performance; depression; fatigue.
Very low to 
moderate
Psychological 
treatments16
Dementia/treatment  
as usual.
Benefit: depression; clinician rated-anxiety.
No effect: self-rated anxiety; caregiver-rated anxiety.
Low to moderate
Aromatherapy17 Dementia/placebo.
Benefit: agitation; behavioral symptoms.
No effect: quality of life; activities of daily living.  
Adverse effects: not found.
Very low
Light therapy18 Dementia/placebo.
Benefit: activities of daily living. No effect: cognition; sleep; challenging 
behavior; psychiatric symptoms.
Not assessed
Cognitive training20
Alzheimer’s disease; 
vascular dementia/
control in the short term.
No effect: overall measurement of cognition, participant’s capacity for 
activities of daily living, participant’s mood, immediate verbal memory 
scores, self-reported burden of care.
Low to moderate
Cognitive rehabilitation20
Alzheimer’s disease; 
vascular dementia/
control in the short term.
Benefit: participant’s self-reported performance in relation to individual 
goals; participant’s mood; self-reported mood.
High
Cognitive stimulation22 Dementia/control.
Benefit: cognition; self-reported quality of life and well-being; staff ratings 
of communication and social interaction.
No effect: mood; activities of daily living; general behavioral function; 
behavioral problem.
Not assessed
Hyperbaric oxygen 
therapy plus donepezil23
Vascular dementia/
donepezil alone.
Benefit: cognition. Not assessed
Functional analysis24 Dementia/usual care. Benefit: frequency of challenging behavior; caregiver reaction. Not assessed
Carbohydrates 
(glucose drink)25
Normal cognition;  
mild cognitive 
impairment/placebo.
Benefit: switch condition of the modified Stroop test; computerized test 
of divided attention.
Not assessed
Enteral tube feeding27
Advanced dementia with 
problems in eating and 
swallowing and/or poor 
nutritional intake/no 
feeding tube.
No effect: survival; nutritional status; prevalence of pressure ulcers. Not assessed
Adjunctive therapies28
AIDS dementia  
complex/placebo.
No effect: neuropsychological test scores; number of patients who completed 
the assigned dosage of experimental medication; all-cause mortality.
Adverse effects: not found.
Not assessed
Acupuncture29 Vascular dementia. No results. No results
Reminiscence therapy31
Dementia/no treatment/
social contact.
Benefit: cognition; mood; general behavior function; staff knowledge of 
group members’ backgrounds.
Adverse effects: not found.
Not assessed
Continue...
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*GRADE = Grading of Recommendations Assessment, Development and Evaluation. Tool used for assessing the quality of the body of the current evidence. 
High quality: low probability that further studies might change the confidence regarding the existing evidence. Moderate quality: probability that further 
studies will change the confidence regarding the existing evidence. Low quality: high probability that further studies will change the confidence regarding the 
existing evidence. Very low quality:  there is much uncertainty about the information, precluding any valid interpretation.36
Intervention Population/comparison Benefits, harms and safety
Evidence quality 
(GRADE approach*)
Transcutaneous 
electrical nerve 
stimulation32
Dementia/placebo.
Benefit: delayed 8-word recall right after treatment; face recognition 
right after treatment; motivation right after treatment. No effect: 
neuropsychological measurements after 6 weeks; behavioral 
measurements after 6 weeks.
Not assessed
Validation therapy33
Cognitive impairment; 
dementia/usual care.
Benefit: behavior. Not assessed
Validation therapy33
Cognitive impairment; 
dementia/social contact.
Benefit: depression. Not assessed
Snoezelen34 Dementia/control. No effect: behavior; mood; communication/interaction; cognition. Not assessed
Table 2. Continuation.
1. Palliative care interventions 
The review12 (2016) had the purpose of assessing the effective-
ness of palliative care interventions in cases of advanced demen-
tia, with inclusion of two randomized controlled trials (RCTs). 
Because of the heterogeneity of the data, no meta-analysis could 
be done. The results listed below were found:
• Palliative care team for people with advanced dementia hos-
pitalized for an acute illness (99 participants): no evidence of 
in-hospital mortality [risk ratio (RR) 1.06, 95% confidence 
interval (CI) 0.53 to 2.13], cardiopulmonary resuscitation, or 
clinical care provided during hospital admission;
• Structured decision-making aid for feeding options among 
surrogate decision-makers of nursing-home residents with 
advanced dementia (total of 90 participants included): lower 
scores for decisional conflict [mean difference (MD) -0.30, 95% 
CI -0.61 to 0.01] in the group of intervention surrogates and 
more likelihood of discuss feeding options with a clinician, 
in comparison with the control group (RR 1.57, 95% CI 0.93 
to 2.64).
There was insufficient evidence to assess the effect of palliative 
care interventions on advanced dementia. For further details, refer 
to the original abstract, available at: http://onlinelibrary.wiley.com/
doi/10.1002/14651858.CD011513.pub2/abstract.
2. Physical exercise programs 
The objective of the review13 (2015) was to analyze physical exer-
cise programs for dementia on different outcomes, such as cog-
nition, activities of daily living, neuropsychiatric symptoms, 
depression and mortality, and the secondary outcomes from the 
intervention (on family caregivers and on use of healthcare ser-
vices). A meta-analysis on 17 trials (1067 participants) showed the 
following results (exercise versus usual care/social group activity):
• Activities of daily living: benefit from exercise programs 
[six  trials, 289 participants; standardized mean difference 
(SMD) 0.68; 95% CI 0.08 to 1.27, P = 0.02);
• Cognitive functioning: no clear evidence (nine studies, 409 par-
ticipants; SMD 0.43; 95% CI -0.05 to 0.92, P = 0.08);
• Neuropsychiatric symptoms and depression: no clear evidence. 
For neuropsychiatric symptoms: one trial, 110 participants; 
MD -0.60; 95% CI -4.22 to 3.02; P = 0.75; for depression: five 
trials, 341 participants; SMD 0.14; 95% CI -0.07 to 0.36; P = 0.16;
• Caregiver burden: may be reduced when the caregiver super-
vises the patient in an exercise program (one trial, 40 partici-
pants; MD -15.30; 95% CI -24.73 to -5.87; P = 0.001);
• Other secondary outcomes could not be assessed.
There was promising evidence that exercise programs might 
improve the ability of people with dementia to perform activities 
of daily living, but no evidence of benefit regarding cognition, neu-
ropsychiatric symptoms, or depression. For further details, refer to 
the original abstract, available at: http://onlinelibrary.wiley.com/
doi/10.1002/14651858.CD006489.pub4/abstract.
3. Case management approaches to home support 
Case management is an intervention for organizing and coordinat-
ing care at the level of the individual, providing long-term care for 
people with dementia in the community. The aim of the review14 
(2015) was to evaluate the effect of case management approaches 
to home support for dementia, from the perspectives of the dif-
ferent parties involved (patients, caregivers and staff). It included 
13  RCTs (9615 participants). The following results were found 
(comparison of case management versus other treatments):
• Total cost of services: reduction in the case management group 
at 12 months (two RCTs, n = 5,276; SMD -0.07, 95% CI -0.12 
to -0.02, P = 0.01);
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Intervention Population/comparison Benefits, harms and safety
Evidence quality 
(GRADE approach*)
Exercise programs13
Dementia/usual care; 
social group activity.
Benefit: caregiver burden.
Very low to 
moderate
Respite care19
Dementia; caregivers/not 
respite care.
No effect: caregiver burden; caregiver psychological stress and health. Very low
Respite care19
Caregivers/polarity 
therapy.
Harm: caregiver perceived stress.
No effect: other psychological health measures;  
other caregiver outcomes.
Very low
Reminiscence therapy31
Dementia/no treatment; 
social contact.
Benefit: caregiver strain.
Adverse effects: not found.
Not assessed
Table 3. Characteristics, main findings and quality of evidence from systematic reviews focusing on caregiver-directed interventions
*GRADE = Grading of Recommendations Assessment, Development and Evaluation. Tool used for assessing the quality of the body of the current evidence. 
High quality: low probability that further studies might change the confidence regarding the existing evidence. Moderate quality: probability that further 
studies will change the confidence regarding the existing evidence. Low quality: high probability that further studies will change the confidence regarding the 
existing evidence. Very low quality:  there is much uncertainty about the information, precluding any valid interpretation.36
Intervention
Population and 
comparison
Benefits, harms and safety
Evidence quality 
(GRADE approach*)
Palliative care team12
Advanced dementia 
hospitalized for acute 
illness/usual care.
No effect: modification on clinical care provided  
during hospital admission; mortality in hospital;  
decisions to forgo cardiopulmonary resuscitation
Very low
Structured aid for 
decision-making on 
feeding options12
Advanced dementia  
in nursing  
homes/usual care.
Benefit: conflict on decisions; likelihood of  
discussing feeding options with a clinician.
Very low
Case management 
approaches14
Dementia; home setting/
other treatments.
Benefit: number of days/month in a residential home/hospital unit; 
total cost of servicers; dollar expenditure (3 years); institutionalization (6 
months); behavior disturbance (18 months); caregiver burden (6 months); 
caregiver depression; caregiver wellbeing (6 months).
No effect: number of people admitted to hospital; length of time until 
participants were institutionalized; institutionalization (10-12 and 24 
months); mortality; participants’ quality of life; behavior disturbance (4, 
6 and 12 months); caregivers’ quality of life; caregiver burden (12 and 18 
months); caregiver well-being (12 and 18 months).
Low to high
Non-specialist 
healthcare worker 
interventions21
Dementia; caregivers/
usual healthcare services.
Benefit: behavioral symptoms; caregiver mental wellbeing;  
caregiver burden; caregiver distress.
Moderate
Special care units26
Dementia/traditional 
nursing homes.
Benefit: use of restraints; mood; Neuropsychiatric inventory score.
Harm: use of psychotropic medication.
Not assessed
Non-pharmacological 
interventions for 
preventing wandering30
Dementia in the domestic 
setting.
No results. No results
Subjective barriers for 
preventing wandering35
Cognitively-impaired 
individuals.
No results. No results
Table 4. Characteristics, main findings and quality of evidence from systematic reviews focusing on healthcare system interventions
*GRADE = Grading of Recommendations Assessment, Development and Evaluation. Tool used for assessing the quality of the body of the current evidence. 
High quality: low probability that further studies might change the confidence regarding the existing evidence. Moderate quality: probability that further 
studies will change the confidence regarding the existing evidence. Low quality: high probability that further studies will change the confidence regarding the 
existing evidence. Very low quality:  there is much uncertainty about the information, precluding any valid interpretation.36
• Dollar expenditure: reduction for the total of three years (one RCT, 
n = 5170; MD -705.00, 95% CI -1170.31 to -239.69, P = 0.003);
• Number of days per month in a residential home or hospital 
unit: reduction in the case management group at six months 
(one RCT, n = 88; MD -5.80, 95% CI -7.93 to -3.67, P < 0.0001) 
and at 12 months (one RCT, n = 88; MD -7.70, 95% CI -9.38 
to -6.02, P < 0.0001);
• Number of people admitted to hospital: no differences at six 
months (four RCTs, 439 participants), 12 months (five RCTs, 
585 participants) and 18 months (five RCTs, 613 participants);
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• Length of time until participants were institutionalized: uncer-
tain effects at 12 months (one trial; hazard ratio (HR): 0.66, 
95% CI 0.38 to 1.14, P = 0.14);
• Institutionalization (admission to residential or nursing homes): 
significantly less likely for case management group at six months 
(six RCTs, n = 5741; OR 0.82, 95% CI 0.69 to 0.98, I² = 0%, 
P = 0.02) and at 18 months (four RCTs, n = 363; OR 0.25, 95% 
CI 0.10 to 0.61, I² = 0%, P = 0.003). The effects were uncer-
tain at 10 to 12 months (nine RCTs, n = 5990; OR 0.95, 95% 
CI 0.83 to 1.08, I² = 48%, P = 0.39) and at 24 months (two RCTs, 
n = 201; OR 1.03, 95% CI 0.52 to 2.03, I² = 0%, P = 0.94);
• Mortality and participants’ or caregivers’ quality of life: no 
significant events (mortality: at four, six, 12, 18, 24 and 36 
months; quality of life: at four, six, 12 and 18 months);
• Behavioral disorder: reduction in case management group at 
18 months (2 RCTs, n = 206; SMD -0.35, 95% CI -0.63 to -0.07, 
I² = 0%, P = 0.01) but uncertain effects at four months (two 
RCTs), six months (four RCTs) and 12 months (five RCTs);
• Caregiver burden: benefits at six months (four RCTs, n = 4601; 
SMD -0.07, 95% CI -0.12 to -0.01, I² = 26%, P = 0.03) but 
uncertain effects at 12 or 18 months;
• Caregiver depression: small significant improvement in case 
management group at 18 months (three RCTs, n = 2,888; SMD 
-0.08, 95% CI -0.16 to -0.01, I² = 0%, P = 0.03);
• Caregiver wellbeing: greater improvement in the case manage-
ment group at six months (one RCT, n = 65; MD -2.20 CI -4.14 
to -0.26, P = 0.03) but uncertain effects at 12 or 18 months.
There was evidence that case management was beneficial for 
improving some outcomes relating to patients and caregivers and 
for lowering admissions to care homes and overall healthcare costs. 
There was not enough evidence regarding whether case manage-
ment might delay institutionalization in care homes, and there were 
uncertain results regarding patient depression, functional abilities 
and cognition. For further details, refer to the original abstract, 
available at: http://onlinelibrary.wiley.com/doi/10.1002/14651858.
CD008345.pub2/abstract.
4. Neuropsychological rehabilitation on multiple sclerosis 
Cognitive deficits are a common manifestation of multiple scle-
rosis (MS). The review15 (2014) aimed to assess the effects of neu-
ropsychological/cognitive rehabilitation on health-related fac-
tors (cognitive performance and emotional well-being) among 
patients with MS, and included 20 studies (986 participants, 
mean age of 44.6 years and 70% women). The results are listed 
below (comparison: intervention versus control):
• Cognitive training: improvement of memory span (SMD 0.54, 
95% CI 0.20 to 0.88, P = 0.002) and of working memory 
(SMD 0.33, 95% CI 0.09 to 0.57, P = 0.006). No evidence of 
effect on emotional functions, attention, information pro-
cessing speed, immediate verbal memory, executive func-
tions or depression;
• Cognitive training combined with other neuropsychological 
rehabilitation methods: improvement of attention (SMD 0.15, 
95% CI 0.01 to 0.28, P = 0.03), of immediate verbal memory 
(SMD 0.31, 95% CI 0.08 to 0.54, P = 0.008) and of delayed 
memory (SMD 0.22, 95% CI 0.02 to 0.42, P = 0.03). No evi-
dence of effect on emotional function, attention, information 
processing speed, everyday cognitive performance, depression 
or fatigue.
The review found low-level evidence of positive effects from 
neuropsychological rehabilitation in relation to MS. For further 
details, refer to the original abstract, available at: http://onlineli-
brary.wiley.com/doi/10.1002/14651858.CD009131.pub3/abstract.
5. Psychological treatments 
Anxiety and depressive symptoms are very common in cases of 
dementia and mild cognitive impairment. The purpose of the 
review16 (2014) was to assess the effectiveness of psychological 
interventions (cognitive behavioral therapy, interpersonal ther-
apy, counselling and others) on anxiety and depression in cases 
of dementia and mild cognitive impairment. It included six RCTs 
on dementia (439 participants, six to 12 months of interven-
tion). No studies focusing on mild cognitive impairment were 
included. The results listed below were found (comparison: psy-
chological treatment versus treatment as usual):
• Depression: positive effect from psychological treatments (six 
trials, 439 participants; SMD -0.22, 95% CI -0.41 to -0.03);
• Clinician-rated anxiety: positive effect from  psychological treat-
ments (two trials, 65 participants; MD -4.57, 95% CI -7.81 to -1.32);
• Self-rated and caregiver-rated anxiety: no difference (for self-
rated: two trials, SMD 0.05, 95% CI -0.44 to 0.54; for caregiver-
rated: one trial, MD -2.40, 95% CI -4.96 to 0.16).
There was evidence that psychological interventions combined 
with usual care could reduce the symptoms of depression and 
clinician-rated anxiety among people with dementia. For further 
details, refer to the original abstract, available at: http://onlineli-
brary.wiley.com/doi/10.1002/14651858.CD009125.pub2/abstract.
6. Aromatherapy 
The objective of the review17 (2014) was to assess the effectiveness 
of aromatherapy for treating dementia. Seven RCTs (428  par-
ticipants, three to 12 weeks of intervention) were included in 
this review, but only two were combined in a meta-analysis. 
The results listed below were found (comparison: aromatherapy 
versus placebo):
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• Agitation and behavioral symptoms: significant treatment 
effect from aromatherapy (one study; for agitation: n = 71, 
MD -11.1, 95% CI -19.9 to -2.2; for behavioral symptoms: 
n = 71, MD -15.8, 95% CI -24.4 to -7.2) versus no difference 
(one study; for agitation: n = 63, MD 0.00, 95% CI -1.36 to 
1.36; for behavioral symptoms: n = 63, MD 2.80, 95% CI -5.84 
to 11.44);
• Quality of life and activities of daily living: no difference in the 
comparison (one study; for quality of life: n = 63, MD 19.00, 
95% CI -23.12 to 61.12; for activities of daily living: n = 63, 
MD -0.50, 95% CI -1.79 to 0.79);
• Adverse effects: no difference (two studies, n = 124; RR 0.97, 
95% CI 0.15 to 6.46).
The benefits of aromatherapy for people with dementia were 
equivocal according to this review. For further details, refer to 
the original abstract, available at: http://onlinelibrary.wiley.com/
doi/10.1002/14651858.CD003150.pub2/abstract.
7. Light therapy 
Stimulation of suprachiasmatic nuclei using light might have the 
potential to reverse circadian disturbances in cases of demen-
tia. The review18 (2014) examined the effect of light therapy on 
cognition, activities of daily living, sleep, challenging behav-
ior and psychiatric symptoms associated with dementia, and 
included 11 trials (499 participants), among which only 8 could 
be combined in a meta-analysis. The following results were found 
( comparison: light therapy versus placebo):
• Activities of daily living: reduction in the development of limi-
tations (one study);
• Cognitive function, sleep, challenging behavior or psychiatric 
symptoms associated with dementia: no effect.
There was insufficient evidence to justify the use of bright-
light therapy in cases of dementia. For further details, refer to 
the original abstract, available at: http://onlinelibrary.wiley.com/
doi/10.1002/14651858.CD003946.pub4/abstract.
8. Respite care 
Respite care is any intervention designed to give rest or relief 
to caregivers. The review19 (2014) aimed to assess the effect of 
respite care on dementia patients and their caregivers, particu-
larly regarding institutionalization rates. Four trials (753 partici-
pants) were included, but no meta-analysis could be done. The 
following results were found:
• Respite care versus no respite care: no significant effects on care-
giver variables (burden and psychological stress and health);
• Respite care versus polarity therapy: significant effect found in 
favor of polarity therapy for caregiver-perceived stress (n = 38, 
MD 5.80, 95% CI 1.43 to 10.17), but not for other psychologi-
cal health measures and other caregiver outcomes;
• Outcomes for people with dementia: not reported in the studies.
The current evidence did not demonstrate any benefits or 
adverse effects from the use of respite care, for people with dementia 
or their caregivers. For further details, refer to the original abstract, 
available at: http://onlinelibrary.wiley.com/doi/10.1002/14651858.
CD004396.pub3/abstract.
9. Cognitive training and cognitive rehabilitation 
Cognitive training and cognitive rehabilitation are interventions 
for improving memory and other aspects of cognitive function-
ing. The review20 (2013) aimed to evaluate the effectiveness of 
these two types of interventions for Alzheimer’s disease or vas-
cular dementia, including 11 trials (383 participants receiving 
interventions from four to 24 weeks) on cognitive training and 
one on rehabilitation. The following results were found (compar-
ison: intervention versus control over the short term):
• Cognitive training: no effect on any outcomes (overall mea-
surement of cognition, participant’s capacity for activities of 
daily living, participant’s mood, immediate verbal memory 
scores and self-reported burden of care);
• Cognitive rehabilitation: no meta-analysis could be conducted. 
However, promising results were found for other outcomes 
(participant’s self-reported performance in relation to indi-
vidual goals, participant’s mood and self-reported mood).
This review did not provide evidence to confirm that cogni-
tive training is effective. Although the results regarding cognitive 
rehabilitation were positive, they were considered preliminary in 
nature. For further details, refer to the original abstract, available at: 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003260.
pub2/abstract.
10. Interventions to care for mental disorders, conducted by non-
specialist healthcare workers 
A significant number of people suffering from mental, neurologi-
cal and substance-use disorders do not receive adequate health-
care. Use of non-specialist healthcare workers and other profes-
sionals involved in healthcare is a key strategy for closing the 
treatment gap. The objective of the review21 (2013) was to assess 
the effectiveness of non-specialist healthcare workers and other 
professionals involved in healthcare in delivering interventions 
relating to mental, neurological and substance-use disorders 
within primary and community healthcare, in low and middle-
income countries. Thirty-eight studies were included, among 
which 22 involved use of lay healthcare workers. For the pur-
poses of our study, results from populations other than dementia 
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patients are not shown (comparison: non-specialist healthcare 
workers versus usual healthcare services):
• Behavioral symptoms of dementia: improvement for the inter-
vention group (severity of behavioral symptoms: SMD -0.26, 
95% CI -0.60 to 0.08);
• Mental wellbeing, burden and distress of caregivers of people 
with dementia: improvement for the intervention group (care-
giver burden: SMD -0.50, 95% CI -0.84 to -0.15).
Use of non-specialist healthcare workers and teachers provided 
some promising benefits in relation to improving patient and care-
giver outcomes in cases of dementia. For further details, refer to 
the original abstract, available at: http://onlinelibrary.wiley.com/
doi/10.1002/14651858.CD009149.pub2/abstract.
11. Cognitive stimulation 
Cognitive stimulation (CS) includes implementation of enjoy-
able activities that provide general stimulation for thinking, con-
centration and memory. The purpose of the review22 (2012) was 
to evaluate the effects of CS on cognition in cases of dementia, 
and included 15 RCTs (718 patients). The following results were 
found (comparison: CS versus control):
• Cognitive function: benefit from CS even three months after 
the treatment (SMD 0.41, 95% CI 0.25 to 0.57);
• Self-reported quality of life and well-being: benefit from CS 
(SMD 0.38, 95% CI: 0.11, 0.65);
• Staff ratings of communication and social interaction: benefit 
from CS (SMD 0.44, 95% CI 0.17 to 0.71);
• Mood, activities of daily living, general behavioral function 
and behavioral problems: no effect.
There was consistent evidence that cognitive stimulation ben-
efited cognition in cases of dementia. For further details, refer to 
the original abstract, available at: http://onlinelibrary.wiley.com/
doi/10.1002/14651858.CD005562.pub2/abstract.
12. Hyperbaric oxygen therapy for treating vascular dementia 
Hyperbaric oxygen therapy (HBOT) has shown possible efficacy 
for treating vascular dementia. The aim of the review23 (2012) 
was to assess the effectiveness and safety of HBOT in treating 
vascular dementia, alone or as an adjuvant treatment. One study 
(64 patients) was included, showing the results below (compari-
son: HBOT plus donepezil versus donepezil alone):
• Cognitive function: benefits for the group receiving HBOT plus 
donepezil, which showed improvements after 12 weeks of treat-
ment (Mini-Mental State Examination: weighted mean differ-
ence (WMD) 3.50; 95% CI 0.91 to 6.09; Hasegawa’s Dementia 
Rating Scale: WMD 3.10; 95% CI 1.16 to 5.04);
• Other outcomes and adverse effects: not measured in this study.
There was insufficient evidence to support HBOT as an effec-
tive treatment for patients with vascular disease. For further details, 
refer to the original abstract, available at: http://onlinelibrary.wiley.
com/doi/10.1002/14651858.CD009425.pub2/abstract.
13. Functional analysis 
Functional analysis (FA) is a promising behavioral intervention 
that involves exploring the meaning or purpose of an individ-
ual’s behavior. The review24 (2012) had the objective of assess-
ing the effects of FA-based interventions relating to people with 
dementia and their caregivers. It included 18 trials, of which 14 
included FA embedded in a broad multicomponent care pro-
gram, which made it impossible to establish the effect of FA 
itself. The results showed (comparison: care program with FA 
versus usual care) that, for the frequency of challenging behav-
ior and caregiver reaction, positive effects after the intervention 
were not assessed at the follow-up phase. The findings suggested 
that FA embedded in multicomponent interventions potentially 
had beneficial effects, but that it was precipitous to draw con-
clusions about its effectiveness. For further details, refer to the 
original abstract, available at: http://onlinelibrary.wiley.com/
doi/10.1002/14651858.CD006929.pub2/abstract.
14. Carbohydrates for cognition 
Carbohydrates are essential and easily accessible macronutrients 
that influence cognitive performance. The aim of the review25 
(2011) was to assess the effect of carbohydrates on cognitive func-
tion in situations of normal cognition and mild cognitive impair-
ment. One study (44 adults, aged 60 to 80 years) was included 
and the following results were found (comparison: glucose drink 
versus placebo, drunk on a single occasion):
• Switch condition of the modified Stroop test: glucose drinkers 
were significantly faster (F 1, 41 = 10.47; P < 0.01);
• Computerized test on divided attention: participants in the 
glucose group showed significantly lower dual-task cost (F 1, 
38 = 8.49; P < 0.01, ² = 0.18).
There was insufficient evidence to base any recommendations 
regarding use of any form of carbohydrate for enhancing cogni-
tive performance. For further details, refer to the original abstract, 
available at: http://onlinelibrary.wiley.com/doi/10.1002/14651858.
CD007220.pub2/abstract.
15. Special care units for behavioral problems 
The purpose of special care units (SCUs) is to optimize care for 
dementia patients, particularly those with behavioral disorders. 
The review26 (2009) aimed to evaluate the effect of SCUs on behav-
ioral problems, mood, need for use of restraints and use of psy-
chotropics in treating dementia. Since no RCTs met the inclusion 
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criteria, eight non-RCTs were selected, among which only four 
could be combined in a meta-analysis. The following results were 
found (comparison: SCUs versus traditional nursing home):
• Need for use of restraints: less need for use of restraints in SCUs 
after six months (two studies, OR 0.46, 95% CI 0.27 to 0.80, 
P = 0.006) and 12 months (one study, OR 0.49, 95% CI 0.27 
to 0.88, P = 0.02);
• Mood: reduction of depressive symptoms among patients at 
SCUs after three months (one study, WMD -6.30 (-7.88 to 
-4.72) Cornell points, P < 0.00001);
• Neuropsychiatric inventory score: limited improvements for 
patients at SCUs (one study lasting six, 12 and 18 months);
• Use of psychotropic medication: reduced use in traditional 
nursing home after six months (one study, WMD 0.20, CI 0.00 
to 0.40, z = 1.96, P = 0.05);
• Behavioral symptoms: no studies found.
There was no strong evidence of benefit, considering the results 
from non-RCTs. For further details, refer to the original abstract, 
available at: http://onlinelibrary.wiley.com/doi/10.1002/14651858.
CD006470.pub2/abstract.
16. Enteral tube feeding 
Use of enteral tube feeding for patients with advanced dementia 
with poor nutritional intake is a frequent practice. The review27 
(2009) aimed to evaluate enteral tube nutrition for patients with 
advanced dementia with eating and swallowing difficulties and/
or poor nutritional intake. Seven observational controlled stud-
ies were identified. In the comparison of feeding tube versus no 
feeding tube, survival, nutritional status and prevalence of pres-
sure ulcers, there was no evidence of benefit among patients 
receiving enteral tube feeding.
There was insufficient evidence to suggest that enteral tube 
feeding was beneficial among patients with advanced demen-
tia. For further details, refer to the original abstract, available at: 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007209.
pub2/abstract.
17. Adjunctive therapies for treating AIDS dementia complex 
AIDS dementia complex is a complication from human immuno-
deficiency virus type 1. The review28 (2008) had the aim of deter-
mining the efficacy and safety of adjunctive therapies for treating 
AIDS dementia complex. Ten trials were included (711 partici-
pants). The results are shown below (comparison: 10 different 
treatments versus placebo):
• Neuropsychological test scores, number of patients who com-
pleted the assigned dosage of experimental medication and 
all-cause mortality: no significant differences between groups;
• Adverse effects: no difference between groups.
This study confirmed that there was no evidence that adjunc-
tive therapies improved cognitive performance or quality of life 
among patients with AIDS dementia complex. For further details, 
refer to the original abstract, available at: http://onlinelibrary.wiley.
com/doi/10.1002/14651858.CD006496.pub2/abstract.
18. Acupuncture for treating vascular dementia 
Use of different acupuncture techniques for treating vascu-
lar dementia is an accepted practice in China. The aim of the 
review29 (2007) was to assess the effects of acupuncture therapy 
for treating vascular dementia. In the absence of any suitable 
RCTs in this field, the authors were unable to perform a meta-
analysis. Therefore, the effectiveness of acupuncture for treating 
vascular dementia is highly uncertain. For further details, refer to 
the original abstract, available at: http://onlinelibrary.wiley.com/
doi/10.1002/14651858.CD004987.pub2/abstract.
19. Non-pharmacological interventions for preventing 
wandering 
Although there seems to be a consensus in the literature that, in 
the majority of cases, non-pharmacological approaches for pre-
venting wandering may work as well as drug treatment and with 
fewer side effects, clinicians often resort to drugs as the first-line 
treatment for this condition. The aim of the review30 (2007) was 
to evaluate the effect and safety of non-pharmacological inter-
ventions to prevent wandering among people with dementia 
(domestic setting). No suitable trials on this subject were found, 
and therefore no results could be reported. For further details, 
refer to the original abstract, available at: http://onlinelibrary.
wiley.com/doi/10.1002/14651858.CD005994.pub2/abstract.
20. Reminiscence therapy 
Reminiscence therapy (RT) involves discussion of past activities, 
events and experiences, with another person or group of peo-
ple and usually with the aid of representative elements, such as 
photos and music. The objective of the review31 (2005) was to 
assess the effects of this therapy on patients with dementia and 
their caregivers. It included five trials, among which only four 
(144  participants) presented extractable data. The results are 
listed below (comparison: intervention versus no treatment/
social contact):
• Cognition (at follow-up), mood (at follow-up) and general 
behavioral function (at the end of the intervention period): 
statistically significant benefit;
• Caregiver strain: significant decrease for caregivers participat-
ing in groups with their relative affected by dementia;
• Staff knowledge of group members’ backgrounds: significantly 
improvement;
• Harmful effects: not identified.
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In view of the limited number and low quality of studies, 
 the  variation in types of reminiscence work reported and the vari-
ation in results between studies, no robust conclusions could be 
drawn. For further details, refer to the original abstract, available at: 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD001120.
pub2/abstract.
21. Transcutaneous electrical nerve stimulation 
Transcutaneous electrical nerve stimulation (TENS), which con-
sists of application of electrical current through electrodes to the 
skin, may improve cognition and behavior in cases of dementia. 
The purpose of the review32 (2003) was to determine the effect 
and safety of TENS for treating dementia, and also the variation 
in treatment parameters. Nine RCTs were selected, among which 
only three could be included in the meta-analysis. The following 
results were found (comparison: TENS versus placebo):
• Delayed eight-word recall, face recognition and motivation: 
improvement in measurements (four trials) right after treatment;
• Other neuropsychological and behavioral measures: no dif-
ference between groups immediately after treatment or after 
six weeks.
The limited data presented in this study did not allow any 
definite conclusions on the possible benefits of this intervention. 
For further details, refer to the original abstract, available at: http://
onlinelibrary.wiley.com/doi/10.1002/14651858.CD004032/abstract.
22. Validation therapy 
Validation therapy is a form of therapy using specific techniques 
based on acceptance of the reality and personal truth of another 
person’s experience. The objective of the review33 (2003) was to 
evaluate the effect of this intervention for people with cognitive 
impairment or dementia. Three RCTs (116 participants), showed 
the following results:
• Validation therapy versus usual care: validation therapy was 
favored in relation to behavior (one study, six weeks of treat-
ment; MD -5.97, 95% CI -9.43 to -2.51, P = 0.0007);
• Validation therapy versus social contact: validation therapy 
was favored in relation to depression (one study, 12 months 
of intervention; MD -4.01, 95% CI -7.74 to - 0.28, P = 0.04).
There were no other statistically significant differences between 
validation and social contact or between validation and usual therapy. 
For further details, refer to the original abstract, available at: http://
onlinelibrary.wiley.com/doi/10.1002/14651858.CD001394/abstract.
23. Snoezelen stimulation 
Snoezelen consists of multi-sensory stimulation of the primary 
senses of sight, hearing, touch, taste and smell through use of 
lighting effects, tactile surfaces, meditative music and the odor 
of relaxing essential oils. The review34 (2002) aimed to examine 
the effect of Snoezelen on dementia patients and their caregivers. 
Two trials (246 subjects) were included, but they could not com-
pound a meta-analysis. The results are shown below (compari-
son: Snoezelen versus control):
• Behavior, mood and communication/interaction: no effects 
from session-based Snoezelen program or 24-hour integrated 
Snoezelen care over the short or long term;
• Cognition: no effects from session-based Snoezelen program 
over the short or long term.
There was no evidence to show that Snoezelen was efficacious for 
treating dementia. For further details, refer to the original abstract, 
available at: http://onlinelibrary.wiley.com/doi/10.1002/14651858.
CD003152/abstract.
24. Subjective barriers for preventing wandering 
Wandering is a frequent behavioral trait among people with 
dementia, and it may put them at risk. The review35 (2000) aimed 
to assess the effect of subjective exit modifications (visual and 
other selective barriers, such as mirrors, camouflage and grids/
strips of tape) on the wandering behavior of cognitively impaired 
people. No RCTs or controlled trials were found and, in addition, 
other studies were considered unsatisfactory. Therefore, there 
was no evidence that subjective barriers prevented wandering 
among cognitively impaired people. For further details, refer to 
the original abstract, available at: http://onlinelibrary.wiley.com/
doi/10.1002/14651858.CD001932/abstract.
DISCUSSION
This review of systematic reviews compiled through the 
Cochrane library focused on non-pharmacological interventions 
for treating cognitive impairment or dementia, regardless of eti-
ology. It was not our primary objective to assess specific inter-
ventions for a given type of dementia but, rather, to present the 
evidence from up-to-date Cochrane reviews on dementia in gen-
eral. Despite the major importance of this condition, there was 
almost no high-quality evidence for any of the outcomes pro-
posed by the systematic reviews included. The primary studies 
presented limited methodological quality and other limitations, 
such as small sample sizes, lack of reporting of adverse effects and 
short-term measurement of outcomes. Consequently, the authors 
of these systematic reviews were unable to put forward any strong 
recommendations for clinical practice.
Three other previous reviews of systematic reviews37-39 aimed 
to evaluate interventions for treating dementia. The most recent 
of these37 compiled any systematic reviews that evaluated the 
effectiveness of non-pharmacological interventions on behavioral 
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disturbances in cases of dementia. The authors’ conclusions were 
similar to ours. The other review38 focused on any kind of interven-
tion to delay functional decline in cases of dementia. Regarding non-
pharmacological interventions, the authors found only low-quality 
evidence relating to physical exercise and dyadic interventions. 
The earliest review39 found evidence suggesting that hand mas-
sage/gentle touch, music or music therapy and physical exercise 
were effective.
Differently from the others, our review only included Cochrane 
systematic reviews: these are developed based on rigorous explicit 
methods. Another important point is that we included all the out-
comes proposed in the systematic reviews that were included, which 
was not the case for other recent reviews37,38 that addressed spe-
cific outcomes (behavioral disturbances and functional decline).
The limitations of the present study relate to the poor quality 
of the primary studies included in the systematic reviews, which 
lowered the strength of evidence.
Given the low quality of the primary studies, no solid rec-
ommendations for practice could be made. Some interventions 
seem to bring potential benefits in relation to limited outcomes, 
but controlled studies with high methodological quality and ade-
quate sample sizes are needed in order to generate sound practical 
conclusions. The need for well-designed studies focusing on non-
pharmacological interventions is particularly important, consid-
ering the personal, familial and societal burden of dementia and 
considering that many pharmacological interventions might not 
be safe in this particular population.
CONCLUSION
A wide range of non-pharmacological interventions has been 
studied in the context of cognitive impairment and dementia, 
and some have shown potential benefits. However, the strength of 
evidence derived from these studies was considered low overall, 
because of the methodological limitations of the primary studies. 
The 24 Cochrane systematic reviews included in this study 
showed that carbohydrates (glucose drink) and validation 
therapy may be beneficial for treating cognitive impairment. 
For dementia, there are potential benefits from physical exer-
cise programs, cognitive training (alone or in association with 
other neuropsychological rehabilitation methods), psychological 
treatments, aromatherapy, light therapy, cognitive rehabilitation, 
cognitive stimulation, hyperbaric oxygen therapy associated with 
donepezil, functional analysis, reminiscence therapy, transcuta-
neous electrical nerve stimulation, structured aid for decision-
making regarding feeding options, case management approaches, 
interventions from non-specialist healthcare workers and use 
of special care units. No benefits were found from enteral tube 
feeding, adjunctive therapies, acupuncture, Snoezelen, respite 
care, palliative care team, non-pharmacological interventions 
for preventing wandering or subjective barriers for prevent-
ing wandering.
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